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The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects
and cytokine induction. This clinical phase I trial was conducted to examine its toxicity, maximum tolerated dose, pharmacokinetics
(PK) and pharmacodynamics (PD). A secondary objective was to assess its antitumour efficacy. DMXAA was administered every 3
weeks as a 20-min i.v. infusion. Dose escalation initially followed a modified Fibonacci schema but was also guided by PK and toxicity.
A total of 63 patients received 161 courses of DMXAA over 19 dose levels ranging from 6 to 4900mgm
 2. DMXAA was well
tolerated at lower doses and no drug-related myelosuppression was seen. Rapidly reversible dose-limiting toxicities were observed at
4900mgm
 2, including confusion, tremor, slurred speech, visual disturbance, anxiety, urinary incontinence and possible left
ventricular failure. Transient prolongation of the corrected cardiac QT interval was seen in 13 patients evaluated at doses of
2000mgm
 2 and above. A patient with metastatic cervical carcinoma achieved an unconfirmed partial response at 1100mgm
 2,
progressing after eight courses. The results of PK and PD studies are reported separately. DMXAA has antitumour activity at well-
tolerated doses.
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Targeting tumour vasculature as a treatment for cancer is the
subject of much research, with most effort currently directed at
angiogenesis inhibitors. Yet therapies that interrupt existing
tumour vasculature and result in haemorrhagic necrosis of
tumours have been investigated for over a century and were
mostly associated with bacterial infections or their toxins (Chaplin
and Dougherty, 1999). William Coley, who pursued the method
avidly from 1891 (Council on Pharmacy and Chemistry, 1934),
achieved significant cure rates, especially in sarcoma and
lymphoma, using various bacterial toxins both for advanced
disease and as adjuvant therapy (Coley-Nauts et al, 1953). Coley’s
toxins were abandoned in favour of radiotherapy, but more recent
clinical studies with bacterial endotoxins have shown modest
antitumour activity, although systemic toxicity remains dose-
limiting (Otto et al, 1996; DeVore et al, 1997).
In 1947, investigators at the National Cancer Institute observed
that a toxin from the bacterium Serratia marcescens acutely and
irreversibly reduced blood flow to sarcomas in mice, while blood
flow to muscle recovered within 18h (Algire et al, 1947). The
induction of tumour necrosis factor (TNF) by bacterial toxins was
later shown to be the cause of haemorrhagic necrosis in tumours
(Carswell et al, 1975; Old, 1985). Clinical trials of recombinant
human TNF were unable to deliver therapeutic doses systemically
because of toxicity (Spriggs and Yates, 1992), but TNF is highly
effective in conjunction with chemotherapy in isolated limb
perfusion for melanoma and sarcoma, where it has been shown
to have selective tumour vascular effects (Lejeune et al, 1998;
Ruegg et al, 1998; Eggermont and ten Hagen, 2001).
Nonbacterial, tumour vascular-targeting agents could have
advantages over bacterial products in terms of toxicity and
pharmacology. One such agent, flavone acetic acid (FAA), showed
remarkable anticancer activity in murine models (O’Dwyer et al,
1987) but its activity was minimal in clinical trials, although these
were conducted when it was thought to be directly cytotoxic and
its indirect mechanisms of antitumour action were poorly under-
stood (Kerr and Kaye, 1989; Bibby, 1991). Further preclinical
studies at the Auckland Cancer Society Research Centre (ACSRC)
showed that FAA induced TNF production, acute tumour vascular
collapse, haemorrhagic necrosis of tumours and enhanced activity
of immune effector cells (Ching and Baguley, 1987; Smith et al,
1987; Finlay et al, 1988; Zwi et al, 1989, 1992) (Zwi et al, 1990 ID:
286). Few appropriate pharmacodynamic (PD) studies were
performed in the clinical trials of FAA, so it is not known whether
it has significant antivascular or immunological activity in
humans. However, in vitro studies suggested a species difference
in antitumour activity, because FAA induced TNF in murine, but
not human, peripheral blood mononuclear cells (Ching et al, 1994;
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l5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a new analo-
gue of FAA developed in the ACSRC, showed greater activity and
12-fold higher dose-potency than FAA in murine tumour models
(Rewcastle et al, 1991) and appeared to overcome the species
difference in in vitro TNF production (Ching et al, 1994; Philpott
et al, 1997). Dose-limiting toxicity in mice was consistent with
hypotension, and was not strictly related to TNF production
(Philpott et al, 1995). While DMXAA proceeded into clinical
development because of this favourable profile, further studies in
animal tumour models have demonstrated synergistic interactions
between DMXAA with radiotherapy (Wilson et al, 1998),
chemotherapy (particularly taxanes) (Pruijn et al, 1997; Horsman
et al, 1999; Wilson and Baguley 2000; Siim et al, 2002),
bioreductive cytotoxic drugs (Cliffe et al, 1994; Lash et al, 1998),
radioimmunotherapy (Pedley et al, 1996), antibody-directed
enzyme prodrug therapy (ADEPT) (Pedley et al, 1999), thalido-
mide (Cao et al, 1999) and immunotherapy (Kanwar et al, 2001).
Cancer Research UK selected DMXAA for two parallel phase I
trials with different schedules, one in the UK using a weekly
administration schedule (at Mt Vernon Hospital, Northwood, and
Bradford Royal Infirmary, Bradford) and the other in Auckland,
NZ, dosing every 3 weeks. The objectives of the NZ study were to
determine the toxicity of DMXAA, its maximum tolerated dose
(MTD), pharmacokinetics (PK), selected PD end points and, as a
secondary objective, antitumour efficacy. A protocol amendment
permitted evaluation of changes in tumour blood flow by dynamic
magnetic resonance imaging (MRI) and the findings (including
both UK and NZ trial patients) have recently been published
(Galbraith et al, 2002). This report focuses on clinical aspects of
the NZ trial; PD and PK aspects, due to their complexity, will be
reported separately.
MATERIALS AND METHODS
Patients
Eligibility criteria included: patients X18 years with histologically
or cytologically proven cancer refractory or not amenable to
conventional therapy; WHO performance status of 0–2; life
expectancy 43 months; haemoglobin X9gdl
 1, WBC
X3 10
9l
 1, platelets X100 10
9l
 1; creatinine p130mmoll
 1;
bilirubin within normal limits, ALT and alkaline phosphatase
o2  upper limit of normal unless due to liver and/or bone
metastases; coagulation (international normalised ratio (INR) and
activated partial thromboplastin time (APTT)) within normal
limits; not pregnant or lactating (adequate contraception if capable
of child-bearing); no anticancer therapy within 4 weeks (6 weeks
for nitrosoureas and mitomycin C); no other serious medical
conditions, uncontrolled infection or serious infection within 28
days; no glucocorticoid treatment in excess of physiological
replacement doses within 2 weeks; and no concurrent malignan-
cies with the exception of cone-biopsied cervical intraepithelial
neoplasia and adequately treated basal or squamous cell carcinoma
of the skin. All patients gave written informed consent and the
regional ethics committee approved the study.
Drug administration
DMXAA (Figure 1) was formulated as a 20mgml
 1 solution of the
sodium salt in 0.1 M phosphate buffer, pH 7.7 and stored in amber
glass ampoules at room temperature. Exposure of DMXAA to
direct sunlight was avoided to prevent decarboxylation and
precipitation (Rewcastle et al, 1990). A more concentrated
formulation (100mgml
 1 in 0.02 M phosphate buffer, pH 7.9)
was developed in order to reduce infusion volumes at higher doses.
The drug was administered every 3 weeks as a 20-min i.v. infusion
(made up to a minimum volume of 100ml with normal saline)
using Imed 960A or Gemini PC-2 infusion pumps (Alaris Medical
Systems, San Diego, CA, USA). Patients could receive a maximum
of six courses if static disease was seen, but if responding they
could continue to maximum response plus two courses up to a
maximum of 12 courses. No intrapatient dose escalation was
permitted, but when a partial response was observed a protocol
amendment was introduced to allow patients treated at lower doses
to re-enter the trial at a higher dose level (if still eligible) to gain
the opportunity of therapeutic benefit.
Dose escalation
The starting dose of 6mgm
 2 was one-tenth of the LD10 in mice.
Dose escalation was planned to follow a modified Fibonacci
scheme, but could be modified by PK data and the clinical
judgement of the investigators and a protocol amendment
permitted results from the parallel UK phase I study to influence
dose escalation. Three patients were planned at each dose level and
three additional patients were to be entered if any of the following
toxicities occurred: neutrophil nadir o1.0 10
9l
 1; platelet nadir
o75 10
9l
 1; grade 2 neurologic or cardiac toxicity or an increase
of one grade of peripheral neuropathy if present at baseline; grade
3 vomiting not responding to symptomatic treatment or other
grade 3 nonhaematological toxicity. The MTD was defined as the
dose below that at which two of three patients suffered a dose-
limiting toxicity (DLT) due to the drug (neutrophil nadir
o0.5 10
9l
 1 or platelet nadir o25 10
9l
 1 or Grade 2 neuro-
toxicity or Grade 3 other nonhaematological toxicity (excluding
alopecia and nausea)). When DLT was reached, an additional three
patients were to be treated at the previous dose level to determine
the recommended dose for phase II trials.
Patient assessments
Prior to treatment and weekly while on trial each patient had a
history taken, clinical examination and blood tests including
complete blood count (CBC) and differential, INR, APTT,
chemistry and urinalysis. Complete blood count was repeated 24
and 72h after course 1 and 24h after course 4. International
normalised ratio and APTT were repeated 4h after DMXAA
infusion on courses 1 and 4. Blood pressure and heart rate were
monitored from 30min before each infusion to 6h afterwards. On
course 1 (and on course 2 in one patient at each dose level)
patients were hospitalised for 24h to monitor toxicity and PK.
Later in the trial, 24-h urine collections were made immediately
prior to and after DMXAA administration, in order to evaluate
changes in creatinine clearance. The National Cancer Institute of
Canada Clinical Trials Group (NCIC-CTG) Expanded Common
Toxicity Criteria (CTC) was used to assess adverse events.
An electrocardiograph (ECG) was performed prior to trial entry.
When transient prolongation of the cardiac corrected QT interval
(QTc) was noticed in a patient after treatment with DMXAA at
2000mgm
 2, subsequent patients had serial ECGs (in two
patients) or ambulatory digital Holter ECG monitoring (in 12
patients) to evaluate acute changes in the QTc. The QTc was
calculated using Bazett’s formula (QTc¼QT/square root of
O
O
CH2COOH
CH 3
CH 3
Figure 1 Structure of DMXAA.
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lpreceding R-R interval) (Kligfield et al, 1996) and was measured in
multiple ECG traces over the first 6–24h after DMXAA admin-
istration.
Tumour response was assessed clinically each week, by plain
radiographs every 3 weeks and by computed tomography (CT) or
ultrasound scans every 6 weeks. A complete response was defined
as the disappearance of all disease on two assessments at least 4
weeks apart. A partial response was defined as at least 50%
decrease in the sum of the products of bidimensional measure-
ments (or the sum of maximum diameters of lesions where
bidimensional measurements were not feasible) of defined
measurable lesions on two assessments at least 4 weeks apart,
and no lesion should have progressed and no new lesions
appeared. No change (static disease) was defined as less than
50% decrease and less than 25% increase in these measurements.
RESULTS
Patient characteristics
Table 1 summarises the gender, age, performance status, diagnosis
and prior systemic therapy of patients enrolled onto the trial. A
total of 161 courses were administered to 63 patients (60 individual
patients, three of whom were re-enrolled at a higher dose level and
evaluated as new patients). The median number of courses was 2
(range 1–8).
Dose escalation
Table 2 summarises the dose escalation schedule, number of
courses administered and number of patients with DLT at each
dose level. Where the investigators felt that specific toxicities were
not of sufficient clinical concern, dose escalation continued
without the dose level being expanded. One patient experienced
DLT at the highest dose level and dropped one dose level for the
second course, and is therefore represented twice. The dose was
escalated from 6 to 4900mgm
 2 over 19 dose levels. The first
escalation (1.7-fold) followed the planned Fibonacci series, but the
values of the area under the plasma concentration–time curve
(AUC) at the first dose level were much lower (1/30th) than those
predicted from murine data. Therefore, the dose was doubled for
subsequent escalations. A rise in plasma nitrate (one of the PD end
points measured) in a patient at 160mgm
 2 suggested the
possibility of having reached a PD threshold, and further
escalations (1.2–1.5-fold) were guided by toxicity and PK from
both the UK and NZ trials. Dose escalation was not restricted by
nonhaematological toxicities that technically met the protocol
definition for DLT but were not considered of sufficient clinical
significance (such as acute onset of tremor that resolved within
one hour).
General toxicity
Toxicities of DMXAA were markedly different from those of many
cytotoxic drugs, and many patients commented that it was easier
to tolerate than chemotherapy. There was no significant drug-
related neutropenia, thrombocytopenia or coagulopathy, and while
anaemia and lymphocytopenia were common, they were judged
unrelated to DMXAA in the majority of cases. Table 3 summarises
selected drug-related non-haematological toxicities, which estab-
lished the MTD at 3700mgm
 2. At lower dose levels, this drug was
generally well tolerated, with a minority of patients experiencing
mild drug-related toxicity. Acute symptoms included venous
discomfort with the infusion (alleviated by application of a warm
pad), increased tumour pain several hours after the drug infusion
and one patient briefly developed small urticarial lesions. Delayed
toxicities included ‘flu-like’ symptoms (malaise, myalgia, fatigue,
nausea, sweating) on days 2–4 of each course, but no mucositis or
alopecia occurred. Additional acute toxicities were more prevalent
with increasing dose above 1100mgm
 2, with onset of symptoms
during or shortly after the 20-min drug infusion. They were usually
mild and invariably transient, generally resolving between a few
minutes and 4h later, and included nausea and/or vomiting (for
Table 1 Patient characteristics
Characteristic No. of patients
Total patients 63
Gender
Male 21
Female 42
Age (years)
Median 55
Range 24–75
WHO performance status
01 3
12 2
22 8
Tumour primary site
Colon/rectum 20
Ovary 11
Melanoma 6
Lung 5
Breast 3
Cervix 3
Unknown primary 3
Pancreas 2
Oesophagus 2
Kidney 2
Soft-tissue sarcoma 2
Other 4
Previous treatment
Chemotherapy 55
Radiotherapy 25
Biotherapy/hormones 1
None 1
Table 2 Dose escalation schedule
DMXAA dose level
(mgm
 2)
No. of
patients
No. of
courses
Patients
with DLT
6 3 11 0
10.2 3 9 0
20.4 3 6 0
40.8 3 6 0
81.6 3 4 0
160 3 6 0
240 3 7 0
360 3 6 0
500 6 19 0
650 3 6 0
850 3 6 0
1100 3 13 0
1375 3 9 0
1650 3 8 0
2000 3 7 0
2600 3 10 0
3100 3 5 0
3700 7
a 18 1
4900 3
a 53
DLT¼dose-limiting toxicity.
aOne patient treated at both dose levels.
Clinical phase I trial of DMXAA
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lonly a few minutes and not reliably prevented by ondansetron),
sympathetic disturbance (sweating, warm flush, hypotension,
hypertension, bradycardia or tachycardia), altered taste and
neurological disturbance (visual disturbance, tremor, feeling
light-headed and restless). Patients at the higher dose levels also
commonly experienced a brief urge to urinate and/or defecate. One
patient (treated at 1650mgm
 2) had pre-existing impairment of
bladder control and was incontinent of urine immediately
following DMXAA administration. Creatinine clearance (measured
by two sequential 24-h urine collections in 12 patients) did not
change following DMXAA administration at doses ranging from
1375 to 4900mgm
 2 (paired t-test, P¼0.63).
Neurological toxicity
At 4900mgm
 2, acute neurological toxicity was considered dose
limiting in all three patients, even though symptoms resolved
completely within 2h. These included slurred speech (two
patients), confusion and expressive dysphasia (one patient),
moderate anxiety (one patient), severe visual disturbance (one
patient), tremor (two patients) and urinary incontinence (one
patient). Similar neurological toxicity was seen in one patient
treated at 1650mgm
 2 on her second course only, attributed to an
interaction between DMXAA and isocarboxazid, a monoamine
oxidase inhibitor. The features were consistent with the ‘serotonin
syndrome’ (Sporer, 1995) and included difficulty concentrating,
drowsiness, generalised tremor, occasional myoclonic jerks, hyper-
reflexia, bradycardia and hypertension, all resolving within 6h.
Visual disturbance was first reported at 1375mgm
 2 and
symptoms became more prevalent and intense with increasing
dose. Symptoms at lower dose levels included altered colour
vision, blurring (without impairment of visual acuity) and mild
photophobia. Colour vision testing revealed acute deterioration in
colour discrimination, resolving within 4h. Dose-limiting transient
visual disturbance at 4900mgm
 2 included glittering of objects,
harsh contrasts, jerky motion and strobe effects. Pattern and flash
electroretinogram (ERG) showed an acute increase in latency and
reduction in amplitude of certain retinal responses following
DMXAA infusion with subsequent return to baseline over several
hours, and a dose–response relationship was observed. A patient
who received six courses at 3700mgm
 2 showed subclinical
deterioration of pre-infusion ERGs between courses 2 and 6.
Cardiorespiratory toxicity
Transient prolongation of the corrected cardiac QT interval was
seen in all 13 patients evaluated at doses of 2000–4900mgm
 2
(median prolongation 52ms, range 38–100ms). In six of nine
patients with normal baseline QTc values, QTc became abnormally
prolonged (4450ms in males, 4470ms in females) after
treatment with doses of DMXAA of X3100mgm
 2 (Committee
for Proprietary Medicinal Products, 1997). The maximal QTc
prolongation occurred during or within 15min of completion of
the drug infusion with a return to baseline generally over 4–6h
(Figure 2). QTc was prolonged beyond 500ms in four patients with
baseline values of 430, 460, 461 and 501ms and in the first three
patients, this lasted for less than 1h. No clear dose–response
relationship was observed and no ventricular tachyarrhythmia was
seen.
Dyspnoea possibly related to DMXAA was documented in three
patients treated at doses p1100mgm
 2, but each patient had
another more likely explanation. At higher doses, acute dyspnoea
at rest occurred in four patients immediately following DMXAA
infusion. In three of these patients (treated at 2600–3700mgm
 2),
the dyspnoea after DMXAA was minimal, brief (5–25min) and
clinically insignificant. The fourth patient, with moderately severe
chronic obstructive respiratory disease, became very breathless
and anxious 15min after her first course at 4900mgm
 2.
Clinically, she had basal pulmonary inspiratory crackles but no
bronchospasm. Oxygen saturation was normal on breathing air
and the symptoms resolved in about 75min. On her second course,
DMXAA was reduced to 3700mgm
 2 (she is thus represented at
two doses in Table 3) and she again developed dyspnoea, lasting
for about an hour. She had basal inspiratory crackles and a third
heart sound (consistent with left ventricular failure) and these
signs resolved within 2h.
Table 3 Nonhaematological toxicity (drug-related
a)
Maximum grade of toxicity per patient
Nausea and/
or vomiting Venous pain Malaise
Hyper- or
hypotension
Flushing/
sweating
Acute neuro
symptoms Dyspnoea
Dose
(mgm 2)
No. of
patients 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4
63 1 1 1
10.2 3 1 1
20.4 3 1 2
40.8 3
81.6 3 1 1 1
160 3 1 1 1
240 3 1 1
360 3 2 1
500 6 1 2 1 2 1
650 3 2 1 1
850 3 2 1
1100 3 2 3 1 3 1
1375 3 3 1 2
1650 3 3 1 2 1 2
2000 3 2 2 1 1 3
2600 3 2 2 1 2 3 3 1
3100 3 3 2 2 3 3 1
3700 7 6 6 6 7 7 2
4900 3 3 3 3 3 3 1
aAlmost certainly, probably or possibly related to DMXAA. Neuro¼neurological.
Clinical phase I trial of DMXAA
MB Jameson et al
1847
British Journal of Cancer (2003) 88(12), 1844–1850 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lTherapeutic response
A total of 60 patients were evaluable for response. One partial
response was seen in a patient with metastatic squamous
carcinoma of cervix treated at 1100mgm
 2 and previously treated
with bleomycin, etoposide and cisplatin chemotherapy, then
carboplatin. The response was unconfirmed because two small
neck nodes increased in size transiently after the third course then
subsequently regressed again and overall tumour response was
maintained for eight courses (Figure 3). No change was the best
response in 22 patients (35%) at dose levels from 6 to 3700mgm
 2
and the duration exceeded 12 weeks in five patients (8%).
DISCUSSION
This phase I trial of DMXAA has demonstrated clinical antitumour
activity and reduction in tumour blood flow at well-tolerated doses
(Galbraith et al, 2002). The MTD was established as 3700mgm
 2,
and higher doses produced unusual, transient toxicities including
confusion, slurred speech, tremor, restlessness and visual dis-
turbance, as well as transient autonomic changes such as sweating,
tremor, changes in blood pressure and heart rate. The results of the
UK trial of DMXAA are published separately (Rustin et al,
submitted to Br J Cancer), but there was a high degree of
concordance with our results including toxicities, PK, PD and
clinical activity (an unconfirmed partial response was also seen).
Clinical trials of FAA, which is structurally related to DMXAA,
showed differences between the two drugs. While the clinical
toxicities of DMXAA and FAA showed some similarities (warmth,
flushing, sweating, fatigue, myalgia, nausea, vomiting and visual
disturbance), the DLTs of FAA were remarkably different and
included hypotension, diarrhoea, flushing, asthenia and fatigue
(Kerr et al, 1987; Weiss et al, 1988; Kaye et al, 1990; Havlin et al,
1991; Olver et al, 1992). Prolongation of bleeding time was
described (Rubin et al, 1987) and one patient presented with
haemorrhage due to immune thrombocytopenia after five doses of
FAA (Davis et al, 1988). Bleeding time was not measured in this
DMXAA trial, but no significant disturbance of INR and APTT was
seen, nor was any significant thrombocytopenia observed.
A number of other agents, including serotonin, some tubulin-
binding agents and arsenic trioxide, selectively inhibit tumour
blood flow (Stu ¨cker et al, 1992; Ching et al, 1999; Lew et al, 1999).
Combretastatin A-4 phosphate (CA4P), a tubulin-binding agent,
has antivascular activity at doses well below the MTD in both
preclinical and early clinical studies (Rustin et al, 1999),
comparable to those reported with DMXAA (Lash et al, 1998;
Galbraith et al, 2002). However, the blood flow-modifying effect of
CA4P is not entirely tumour-selective (Griggs et al, 2001), and it
appears to be reversible except at high doses (Anderson et al, 2000;
Murata et al, 2001). Some CA4P toxicities resembled those of
DMXAA (including flushing, nausea, vomiting, tumour pain and
QTc prolongation), but others (cardiac ischaemia and cerebellar
ataxia) were notably different (Galbraith et al, 2001; Dowlati et al,
2002).
Some toxicities observed with DMXAA resemble the ‘serotonin
syndrome’, attributed to high levels of serotonin in the central
nervous system (CNS). This syndrome most commonly occurs
when two drugs are taken, which can each increase CNS serotonin
and includes alterations in cognition, behaviour, autonomic
nervous system function and neuromuscular activity (Sporer,
1995). Supportive evidence comes from two other aspects of this
trial: firstly, a patient took a monoamine oxidase inhibitor prior to
treatment with DMXAA at 1650mgm
 2 and developed clinical
features of the serotonin syndrome; and secondly an acute increase
in plasma prolactin levels seen in many patients treated with
DMXAA at X2000mgm
 2 (unpublished results). This occurs
following production of serotonin in the CNS (Van de Kar et al,
1996). If subsequent studies provide further evidence that DMXAA
increases CNS serotonin release, it would be prudent to avoid
administering DMXAA to patients who are receiving other
drugs that increase CNS serotonin levels (Brown et al, 1996).
The mechanism underlying the acute release of CNS serotonin
is not known, but serotonin release in plasma has been observed
in this study (Kestell et al, 2001), and is a feature of the
antivascular activity of this drug in preclinical models (Baguley
et al, 1997).
The visual toxicities of DMXAA are not a feature of the
serotonin syndrome, but the blurring, colour disturbance and
photophobia have similarities to those reported with sildenafil
(Viagra
s, Pfizer, New York, NY, USA) (Marmor and Kessler,
1999). The latter’s visual toxicities are thought to be due to
inhibition of phosphodiesterase type 6 (PDE6), which exists
exclusively in the retina and is responsible for modulating the
transduction cascade of the photoreceptor response to light.
Recent data have shown that DMXAA inhibited PDE6 in vitro at
pharmacologically relevant concentrations (e.g. 50mM) (personal
communication, L Kelland, Antisoma plc). It is reassuring in
this regard that no long-term retinal sequela of sildenafil
administration is known, including data from retinal histologic
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Figure 3 Tumour response in a patient with metastatic squamous
carcinoma of cervix treated with DMXAA 1100mgm
 2. Tumour size was
calculated as the sum of the products of bidimensional measurements of
three clinically measurable metastatic neck nodes.
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lstudies in dogs dosed with 65 times the maximum recommended
human dose daily for 12 months (Wallis et al, 1998; Marmor and
Kessler, 1999).
The significance of the observed QTc prolongation in these
preliminary data is uncertain given its brevity, its possible relation
to autonomic changes caused by the infusion and the population of
patients potentially being treated with this agent. Moreover, the
use of ad hoc heart rate correction formulae (such as Bazett’s) may
bias the result (Aytemir et al, 1999). Therefore the QTc results in
this trial must be regarded as indicative only. However, given the
concern that QT interval prolongation may predispose to
ventricular tachycardia (Committee for Proprietary Medicinal
Products, 1997), it will be important to determine the dose–
response relationship of QTc prolongation before deciding on the
dose of DMXAA for phase II and combination studies.
In conclusion, DMXAA is well tolerated over a wide dose range
and has clinical and biological features distinct from those of other
antivascular drugs in clinical development. Further clinical trials
with this agent are clearly warranted, particularly in combination
with other treatment modalities where synergistic interactions are
observed in animal tumour models.
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